18 completed, 2 terminated, 1 withdrawn. 12 Phase 1, 7 Early Phase 1, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 11, Withdrawn 1 |
| Early Phase 1 | 7 | Completed 5, Terminated 2 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Invicro: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease [18F]MK-0947 - Parkinson's Disease (PD), Parkinson's Disease | Early Phase 1 | Terminated | Invicro | 16 | 2025-12-08 | 2026-07-27 |
| First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate - Progressive Supranuclear Palsy (PSP), Healthy Participants | Early Phase 1 | Completed | Invicro | 11 | 2025-11-17 | 2026-07-10 |
| PET Study of Repeated ASN51 in Healthy Volunteers ASN51 - Healthy | Phase 1 | Completed | Asceneuron S.A. | 12 | 2023-01-26 | 2025-05-08 |
| 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma 131I-Omburtamab, Convention Enhanced Delivery - DIPG | Phase 1 | Withdrawn | Y-mAbs Therapeutics | 2022-03-01 | 2023-06-26 | |
| Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein [18F]UCB-2897 - Parkinson Disease, Multisystem Atrophy | Phase 1 | Completed | Invicro | 5 | 2022-01-31 | 2025-02-20 |
| Plasma P-tau2017 and Quantitative Amyloid PET Imaging Amyvid - Alzheimer Disease | Phase 1 | Completed | Invicro | 140 | 2021-08-27 | 2025-02-28 |
| Occupancy of Adenosine A2A Receptors Using the PET Radiotracer [18F]MNI-444 [18F]MNI-444 - Healthy Volunteer | Phase 1 | Completed | Invicro | 3 | 2021-06-24 | 2022-07-05 |
| Evaluation of [18F]APN-1607 as a PET Biomarker [18F] APN-1607 - Progressive Supranuclear Palsy, Healthy Volunteers | Phase 1 | Completed | Invicro | 12 | 2021-05-25 | 2025-02-20 |
| Study to Evaluate a Potential PET Radioligand for Imaging Alpha-synuclein Deposits in the Brain [18F]MNI-1216 - Alpha-Synucleinopathy, Parkinson's Disease | Early Phase 1 | Completed | Invicro | 12 | 2020-12-24 | 2025-02-19 |
| A Study of the Biodistribution and Safety of [18F]GTP1 in Healthy Japanese Participants [18F]GTP1 - Alzheimer Disease | Phase 1 | Completed | Genentech, Inc. | 6 | 2020-08-11 | 2021-11-03 |
| Safety and Targeting of Anti-hk2 Antibody in mCRPC 111In-DOTA-h11B6 - Castration-Resistant Prostatic Cancer, Metastatic Disease | Early Phase 1 | Terminated | SpectronRX | 27 | 2019-09-18 | 2023-09-25 |
| Do Adolescents and Adults Differ in Their Acute Response to Cannabis? Cannabis with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), Cannabis with THC without CBD, Placebo cannabis - Cannabis, Cannabis Intoxication | Not applicable | Completed | University College, London | 48 | 2019-03-11 | 2021-09-29 |
| Assessment of the Biodistribution and Safety of [18F]MNI-1054 [18F]MNI-1054 - Healthy Volunteers | Phase 1 | Completed | Invicro | 4 | 2018-10-05 | 2019-05-23 |
| D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562 PF-06412562 - Healthy Male Volunteers | Early Phase 1 | Completed | Invicro | 6 | 2018-09-10 | 2019-04-22 |
| Assessment of [18F]MNI-1054 as a Marker for LSD1 [18F]MNI-1054 - Healthy Volunteers (HV) | Early Phase 1 | Completed | Invicro | 4 | 2018-08-09 | 2019-05-23 |
| Evaluation of [18F]MNI-1126 as an Imaging Marker for Synaptic Density Loss [18F]MNI-1126 - Alzheimer Disease, Parkinson Disease | Phase 1 | Completed | Invicro | 12 | 2018-05-07 | 2020-04-15 |
| Phase 1 Test-retest Evaluation of [18F]MNI-958 PET [18F]MNI-958 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Completed | Invicro | 16 | 2018-03-12 | 2020-02-17 |
| Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects [18F]MNI-958 - Healthy Volunteers | Phase 1 | Completed | Invicro | 2 | 2017-11-14 | 2018-10-22 |
| TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort Brain Imaging - Stroke, Ischemic, Inflammatory Response | Not applicable | Completed | Imperial College London | 3 | 2017-08-31 | 2021-06-30 |
| Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein [18F] MNI-946, [18F]Florbetapir - Alzheimer Disease, Healthy Volunteers | Early Phase 1 | Completed | Invicro | 10 | 2016-06-01 | 2021-06-14 |
Showing 20 of 21. Sign in to see all of them.
Alzheimer Disease (5) · Parkinson Disease (4) · Supranuclear Palsy, Progressive (3) · Multiple System Atrophy (2) · Encephalitis (1) · Ischemic Stroke (1) · Lewy Body Disease (1) · Marijuana Abuse (1) · Neoplasm Metastasis (1) · Nerve Degeneration (1) · Neuroendocrine Tumors (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Pick Disease of the Brain (1) · Prostatic Neoplasms, Castration-Resistant (1) · Stroke (1)
florbetapir (3) · Cannabidiol (1) · Dronabinol (1) · MNI-444 (1) · Magnetic Resonance Imaging (1) · Neuroimaging (1) · Positron Emission Tomography Computed Tomography (1) · Positron-Emission Tomography (1) · nabiximols (1) · omburtamab I-131 (1)
United States (16) · United Kingdom (3)
David Russell, M.D., Ph. D (3) · Jennifer Madonia, PA-C (3) · Adeep Puri, MD (1) · Amy Knorr, MD (1) · David Russell (1) · David Russell, M.D., Ph.D (1) · David Russell, M.D., Ph.D. (1) · David Russell, MD (1) · David Russell, MD, Ph.D (1) · Joyce Gibbons, PA-C (1) · Michael J Morris, MD (1) · Rohini Sharma (1)
PMID 35032682, PMID 36642667, PMID 36750134, PMID 38331457, PMID 38416223, PMID 38782459, PMID 39929582